Trial · NCT01227278
Results by group62
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 62
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Annualized Incidence Rate of Moderate or Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) | Placebo | 0.92 | 95% Confidence Interval 0.67 to 1.25 | AECOPD events/person-year | |
| Annualized Incidence Rate of Moderate or Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) | Benralizumab 100 mg | 0.95 | 95% Confidence Interval 0.68 to 1.29 | AECOPD events/person-year | |
| Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Placebo | TEAEs | 41 | participants | |
| Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Benralizumab 100 mg | TEAEs | 45 | participants | |
| Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Placebo | TESAEs | 9 | participants | |
| Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Benralizumab 100 mg | TESAEs | 14 | participants | |
| Number of Participants Hospitalized Due to Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) | Placebo | 5 | participants | ||
| Number of Participants Hospitalized Due to Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) | Benralizumab 100 mg | 2 | participants | ||
| Percentage of Participants Hospitalized Due to Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) | Placebo | 11.9 | percentage of participants | ||
| Percentage of Participants Hospitalized Due to Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) | Benralizumab 100 mg | 5.0 | percentage of participants | ||
| Annual Incidence Rate of Hospitalization Due to Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) | Placebo | 0.11 | 95% Confidence Interval 0.05 to 0.26 | hospitalizations/person-year | |
| Annual Incidence Rate of Hospitalization Due to Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) | Benralizumab 100 mg | 0.05 | 95% Confidence Interval 0.01 to 0.18 | hospitalizations/person-year | |
| Change From Baseline in COPD-Specific Saint George's Respiratory Questionnaire (SGRQ-C) Total and Domain Scores at Day 393 | Placebo | Baseline: Total Score (n=42, 40) | 48.04 | Standard Deviation 19.14 | units on scale |
| Change From Baseline in COPD-Specific Saint George's Respiratory Questionnaire (SGRQ-C) Total and Domain Scores at Day 393 | Benralizumab 100 mg | Baseline: Total Score (n=42, 40) | 51.75 | Standard Deviation 20.45 | units on scale |
| Change From Baseline in COPD-Specific Saint George's Respiratory Questionnaire (SGRQ-C) Total and Domain Scores at Day 393 | Placebo | Change at Day 393: Total Score (n=42, 37) | -4.43 | Standard Deviation 11.71 | units on scale |
| Change From Baseline in COPD-Specific Saint George's Respiratory Questionnaire (SGRQ-C) Total and Domain Scores at Day 393 | Benralizumab 100 mg | Change at Day 393: Total Score (n=42, 37) | -5.51 | Standard Deviation 16.64 | units on scale |
| Change From Baseline in COPD-Specific Saint George's Respiratory Questionnaire (SGRQ-C) Total and Domain Scores at Day 393 | Placebo | Baseline: Symptoms (n=42, 40) | 64.59 | Standard Deviation 24.38 | units on scale |
| Change From Baseline in COPD-Specific Saint George's Respiratory Questionnaire (SGRQ-C) Total and Domain Scores at Day 393 | Benralizumab 100 mg | Baseline: Symptoms (n=42, 40) | 67.18 | Standard Deviation 21.47 | units on scale |
| Change From Baseline in COPD-Specific Saint George's Respiratory Questionnaire (SGRQ-C) Total and Domain Scores at Day 393 | Placebo | Change at Day 393: Symptoms (n=42, 37) | -3.19 | Standard Deviation 17.44 | units on scale |
| Change From Baseline in COPD-Specific Saint George's Respiratory Questionnaire (SGRQ-C) Total and Domain Scores at Day 393 | Benralizumab 100 mg | Change at Day 393: Symptoms (n=42, 37) | -9.02 | Standard Deviation 21.27 | units on scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01227278/results